Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing - Wikidata - awgldk - TriplyDB

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

http://www.wikidata.org/entity/Q28077785

about

Expression of HIF-1α and P-gp in non-small cell lung cancer and the relationship with HPV infection.Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells.

P2860

Q37106809-BB586A2C-238C-4855-9C58-9248C7ECF922 Q52649739-182D2138-CEFA-422A-8398-4840E0543317

P2860

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

http://www.wikidata.org/entity/Q28077785

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

@ast

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

@en

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

@nl

type

label

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

@ast

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

@en

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

@nl

prefLabel

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

@ast

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

@en

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

@nl

P1433

Q28077785-0FB0A56E-C13D-4AE8-8198-BC9492A5542F

P1476

Q28077785-35227A96-08D8-4165-80D1-301E9C074946

P2093

Q28077785-493D4124-9BF0-433A-B6F1-B4BEB934798D

Q28077785-F5914C25-E369-44EC-8F54-4BDAACD01037

P2860

Q28077785-01E91D06-4721-40F6-A1DC-3564805B7783

Q28077785-066D3DDC-4555-4064-9CCB-BDA1ED1B6D83

Q28077785-1277CD1E-727C-4C5E-A2C5-C985666D31D9

Q28077785-1EF3BC7F-EE6E-44C5-95AC-7FB26E5D4796

Q28077785-2DACBEBF-A68B-4967-8F80-6584AFABB3CC

Q28077785-2E9A7D13-9929-4EDD-9271-E88FBAF7EBE9

Q28077785-36A4FED1-4BA9-43F6-8274-7FAE6C7458E5

Q28077785-4B55A558-0465-4E6A-8A71-95E62DC1FB7D

Q28077785-4D2961E8-4D80-4280-BDC9-38DC41E6C23E

Q28077785-5178129D-55DE-44EC-A4D5-5D262542FA63

P304

Q28077785-6AC5A29F-C8C3-4BBF-9574-13C8B7BFCE40

P31

Q28077785-611F132F-2C72-4707-A20E-59CDEEEF5CF8

P3181

Q28077785-F851C2AA-212D-468E-A8C7-E21174D1238C

P356

Q28077785-7EBEE143-5296-4E66-8CA0-303E2EEC033B

P433

Q28077785-AE33E918-A687-42D0-A7C3-E94C3E31F418

P478

Q28077785-2791086F-6A5D-43D2-9E7A-F7C7ECBC8DEC

P577

Q28077785-141AC5E4-8FDB-4B05-AE0E-ABC8120E748B

P698

Q28077785-7CF57B56-3F30-4061-8A9E-B183EF7A3779

P932

Q28077785-9B5BFD02-7926-4837-8B6D-DD922D9D9CA2

P3181

P356

J.ISSN.1009-3419.2015.12.06

P1433

Zhongguo fei ai za zhi

P1476

Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

@en

P2093

Hongge Liang

http://www.w3.org/2001/XMLSchema#string

Mengzhao Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Research Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung Cancer

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.

A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing.

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

Scatter-factor and semaphorin receptors: cell signalling for invasive growth.

Drug development of MET inhibitors: targeting oncogene addiction and expedience.

The evolving genomic classification of lung cancer.

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

P304

745-751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

711710

http://www.w3.org/2001/XMLSchema#string

P356

10.3779/J.ISSN.1009-3419.2015.12.06

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26706951

http://www.w3.org/2001/XMLSchema#string

P932

6015186

http://www.w3.org/2001/XMLSchema#string